Sylvie Marleau
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Neutrophil-targeted liposomal inhibition of PAD4-mediated NETosis in systemic lupus erythematosus.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: March 13, 2026
Cyclic azapeptide CD36 ligand attenuates cardiac injury and reduces long-chain fatty acid accumulation after myocardial ischemia-reperfusion in mice.
Journal: FEBS open bio
Published: October 09, 2025
Nanoformulation of valsartan-loaded tablet attenuates L-NAME-induced hypertension: role of Nrf2/PPARγ/AT1 signaling pathway.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: January 17, 2025
Selective Azapeptide CD36 Ligand MPE-298 Regulates oxLDL-LOX-1-Mediated Inflammation and Mitochondrial Oxidative Stress in Macrophages.
Journal: Cells
Published: October 30, 2024
Targeting CD36 With EP 80317 Reduces Remote Inflammatory Response to Hind Limb Ischemia-Reperfusion in Mice.
Journal: Journal of biochemical and molecular toxicology
Published: September 19, 2024
Monoclonal Antibody chP3R99 Reduces Subendothelial Retention of Atherogenic Lipoproteins in Insulin-Resistant Rats: Acute Treatment Versus Long-Term Protection as an Idiotypic Vaccine for Atherosclerosis.
Journal: Journal of the American Heart Association
Published: June 27, 2024
Pharmacological targeting of the hyper-inflammatory response to SARS-CoV-2-infected K18-hACE2 mice using a cluster of differentiation 36 receptor modulator.
Journal: Frontiers in pharmacology
Published: September 27, 2023
A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice.
Journal: Frontiers in pharmacology
Published: April 12, 2023
Therapeutic applications of nanoparticles targeting neutrophil and extracellular traps.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: January 16, 2023
Optimization of a Liposomal DNase I Formulation with an Extended Circulating Half-Life.
Journal: Molecular pharmaceutics
Published: May 11, 2022
Tailoring PEGylated nanoparticle surface modulates inflammatory response in vascular endothelial cells.
Journal: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
Published: November 01, 2021
Last Updated: 09/26/2026